ACM
APRE icon

Altium Capital Management’s Aprea Therapeutics APRE Stock Holding History

Altium Capital Management’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-137,197
Closed -$558K – 83
2024
Q2 		$558K Buy
+137,197
New +$707K 0.23% 40

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Altium Capital Management's APRE Position: Q3 2024 in Review

Altium Capital Management sold out of Aprea Therapeutics (APRE) in Q3 2024, closing a stake of 137,197 shares — an estimated $558K sold.

Altium Capital Management first reported a position in APRE in Q2 2024 and held it in 1 quarter. The position peaked at $558K in Q2 2024. 22 funds tracked by Wall St. Rank hold APRE as of Q3 2024.

  • Altium Capital Management reported no remaining Aprea Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Altium Capital Management sold 137,197 Aprea Therapeutics shares in Q3 2024, an estimated $558K.
  • Altium Capital Management first reported a position in Aprea Therapeutics in Q2 2024 and held it in 1 quarter.
  • Altium Capital Management's Aprea Therapeutics position peaked at $558K in Q2 2024.
  • 22 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q3 2024.

Based on Altium Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.